November 4, 2024
Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Nicholas A. Eitsert
In September, a relatively favorable month for patent owners, the PTAB cancelled 123 (57.75%) instituted claims across 19 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit. After review, 74 (34.74%) instituted claims survived. Patent owners conceded 16 (7.51%) instituted claims, including through motions to amend. For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 12 (63.16%) decisions, all instituted claims survived in 6 (31.58%) decisions, and a mixed outcome occurred in 1 (5.26%) decision. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.

Through September 30, 2024, the PTAB has cumulatively granted 662 (15.90%) proposed substitute claims in motions to amend while denying 3,501 (84.10%) proposed substitute claims in IPRs.

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through September 30, 2024, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through September 30, 2024, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through September 30, 2024, are available here on the At the PTAB blog.
Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients. Stay tuned to the At the PTAB Blog for the latest updates, analysis, and statistics on all aspects of PTAB practice. Subscribe to receive notifications of new posts via email.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.